

subjective experience, which is exacerbated by fatigue, anxiety and negative expectations of treatment. Studies show that, in addition to antiemetic drugs for nausea, it is important the way in which the patient is introduced to treatment through requisite information and training. A calm environment in combination with professional care plays a major role in the treatment of nausea in cancer therapy. Whatever the reason, it is essential to stop the nausea in order to prevent future complications, ease suffering and enhance well-being.

Methods: The aim was to develop general clinical guidelines in an effort to prevent and relieve nausea and/or vomiting.

An evidence group is a working group with nurse specialists that meets on a regular basis to review evidence-based literature and to formulate and implement guidelines. Today, there are nursing guidelines for cancer-related fatigue, nausea/vomiting, diarrhea and constipation. Work is in progress regarding the symptoms (e.g., anxiety and insomnia) that are known to be associated with cancer disease and treatment.

Results: Guidelines for the management of nausea associated with cancer with or without oncological treatment are under development. For assessment of the expected needs and the optimization of antiemetic therapy, it is important to assess the risk already at the time of the first treatment episode. To improve opportunities to prevent and treat nausea and/or vomiting a simple tool – a symptom diary for nausea and vomiting – is used in which the patient describes his or her symptoms.

The nurse gives instructions in the form of oral and written information on how patients themselves can prevent or relieve nausea and/or vomiting. The nurse documents the results of the patient's medical history, risk assessment and the patient's diary. At the next visit, follow-up and evaluation will take place and a reassessment is made.

Conclusion: The Evidence group will continue to work regarding symptom management. This type of work provides safe, secure and standardized care. Furthermore, the patients' involvement in symptom management is highly visible. Documentation of how patients respond to antiemetic treatment in the form of a diary about their nausea is essential to ensure that the clinic's guidelines for treatment are functioning optimally.

4271

POSTER

Prevalence and Severity of Chemotherapy Related Symptoms and Complications With Inpatient Chemotherapy

M. Folsche¹, F.E. Witkamp¹, E. van Meerten¹, F.C.J.M. van Eekelen¹, M.C. de Ruiter¹, C.C.D. van der Rijt¹. ¹Erasmus MC Daniel den Hoed Cancer Center, Medical Oncology, Rotterdam, The Netherlands

Background: Complications of inpatient chemotherapy (ICT) can cause a threat to the continuity of cancer treatment and can have an impact on quality of life. The aim of our prospective study was to determine the prevalence, the type and the severity of chemotherapy related symptoms (CRS) and complications (CRC) due to standard ICT for solid tumours. Furthermore we wanted to study a possible association between experienced subjective CRS and the severity of observed CRC.

Material and Methods: At the start of every ICT cycle patients (pts) filled in a symptom list. This list contains 14 frequently occurring CRS (anorexia, nausea, vomiting, constipation, diarrhea, stomatitis, fatigue, pain, tinnitus, tingling, worrying, sleeplessness, feeling tense, anxiety) on a 0–10 scale. We defined moderate to severe CRS, when scored >4. The occurrence of 14 possible CRC and possible treatment adaptations were registered by the clinical nurse specialist by using data from the medical record.

Results: From February 1st until December 1st 2010, 90 pts received 279 ICT cycles of 13 different ICT regimens (82.8% cisplatin based), with a median of 3 ICT cycles. Before and after the first ICT cycle, 80 pts registered a median of 2 moderate to severe CRS. Before and after the first cycle 56% resp. 65% reported 1 or more symptoms >4 (mean 3.5 resp. 3.2), with a correlation (Spearman's rho/rs) of 0.42 (p 0.000). The correlation between moderate to severe CRS and CRC after the first cycle was rs 0.34 (p 0.02). Pts suffering from moderate to severe CRS were confronted with an extra or prolonged hospital stay in 16% of the cases and with treatment adaptation in 14% of the cases. After the first cycle 70% of the pts had a total of 156 CRC, resulting in treatment adaptation in 28%: delay (12%), definitive treatment stop (10%) or substitution of a cytostatic agent (6%). After the first cycle 24% of the pts had a prolonged hospital stay or an extra hospital admission, due to CRC. Most CRC leading to treatment adaptation after the first cycle were: renal impairment (14 out of 18 cases) and anamnestic decreased oral intake (11 out of 21 cases).

Conclusions: Pts treated with ICT suffer from CRS and CRC frequently. With 28% of the pts these CRS and CRC lead to adaptation of treatment or to hospital admission.

4272

POSTER

Sleep-wake Disturbances in Patients With Cancer and Informal Caregivers – the Added Value of a Dyadic Approach in Their Assessment and Management

G. Kotronoulas¹, N. Kearney¹, Y. Wengström². ¹University of Dundee, School of Nursing & Midwifery, Dundee, United Kingdom; ²Karolinska Institutet, Department of Neurobiology Care Science and Society – Division of Nursing, Huddinge, Sweden

Background: Over the past twenty years, research has established that people with cancer are in risk of widely disrupted sleep patterns, regardless of the type or stage of disease, or phase of treatment. In spite of the dearth of evidence, sleep of caregivers of patients with cancer also becomes disrupted. One characteristic of the current sleep research is its exclusive focus on the individual; however, recent evidence confirms the shared nature of cancer experience.

Methods: A systematic review of the literature was conducted, which identified only one study concurrently describing sleep patterns in patient-caregiver dyads, as well as six methodologically diverse studies conducted in non-cancer populations.

Results: As patients and caregivers go through the experience of illness together, their emotional reactions and distress affect one another in a relatively proportionate manner: they add to one's own concerns and worries when they reach a peak, possibly resulting in corresponding changes in the dyad's sleep patterns. Similarly, effective or dysfunctional coping strategies of the dyad might co-affect their sleep through a psycho-behavioural mechanism. While it is reasonable that patient symptom distress can lead to increased caregiving effort, disrupted caregiver sleep patterns and increased fatigue coupled with daytime sleepiness, increased caregiver burden can equally lead to poor caregiving performance, which might in turn inhibit management of patient symptoms affecting sleep. As well, although not all patients and caregivers share the same bed or the same room, co-sleeping or co-habiting dyads might be co-affected by poor sleep hygiene practices or by disrupted sleep patterns related to the illness experience. Such sleep mediators might well interfere with the prerequisites necessary for a good night's sleep at a level that transcends the individual.

Conclusions: Drawing on the above arguments, it is assumed that implementation of a dyadic approach would augment our understanding of co-occurrence of sleep problems in patient-caregiver dyads, trends of concurrent transformation of these sleep problems across time, as well as covariates that appear to contribute to these patterns within the dyad and across time. Importantly, such an approach requires longitudinal, adequately powered and designed exploratory and interventional studies to be conducted for the development of truly effective sleep interventions for people affected by cancer.

4273

POSTER

The Nurse as a Source of Information in the Management of Side Effects of Chemotherapy

O. Diamanti¹, M. Giacobbo², D. Grosso³, N. Galtarossa¹, M. Zanocco¹, M. Padovan¹. ¹Istituto Oncologico Veneto, Oncologia Medica, Padua, Italy; ²Istituto Oncologico Veneto, Health Department, Padua, Italy; ³Istituto Oncologico Veneto, Center Trial, Padua, Italy

Introduction: Malnutrition is present in most of 70% of cancer patients. Causes of malnutrition are: lack of appetite, altered taste and smell, mucositis, nausea and vomiting. Nearly half of the patients receiving chemotherapy are not given enough information about the treatment and its side effects. More commonly, patients receive information for the management of nausea and vomiting, information that is given mainly by the oncologist.

Aims of the study: To identify how many and which kind of information are given to patients about the side effects related to malnutrition during chemotherapy and to analyze the sources of these information.

Materials and Methods: The study was conducted at the Day Hospital of the Department of Oncological Medicine adjunct to the "Istituto Oncologico Veneto" in Padua, from May 2009 to July 2009. An ad-hoc 18-item questionnaire was administered to 120 patients who answered/responded to questions about the symptoms of malnutrition and their information sources. The questionnaire was filled out by patients in therapy with: Oxaliplatin, Docetaxel, Caelyx as highly emetic. The interview was conducted with patients by the same person and with the same procedure for all respondents.

Results: Most of patients live as a serious problem (49% of patients) to changes in their eating habits and this affects their quality of life. 43% of the patients claimed to have been informed about side effects of chemotherapy; 40% of the patients had received information by the nurses, while 38% by the physicians; 86% of the patients had received information about